Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PROSPECTIVE PRAGMATIC CLINICAL TRIAL OF CHINA EARLY INVASIVE BREAST CANCER PATIENTS RECEIVING ADJUVANT THERAPY WITH AROMASIN

NCT01176916 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01176916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01176916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PROSPECTIVE PRAGMATIC CLINICAL TRIAL OF CHINA EARLY INVASIVE BREAST CANCER PATIENTS RECEIVING ADJUVANT THERAPY WITH AROMASIN
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
February 9, 2011
Completion date
November 30, 2018
Enrollment
564 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms